Major Scope

  •  Lung Cancer
  •  Colorectal Cancer
  •  Pancreatic Cancer
  •  Breast Cancer
  •  Prostate Cancer
  •  Liver Cancer
  •  Leukemia
  •  Bladder Cancer
  •  Kidney Cancer
  •  Endometrial Cancer
  •  Oncology Case Reports
  •  Radiation Therapy

Abstract

Citation: Clin Oncol. 2019;4(1):1647.DOI: 10.25107/2474-1663-v4-id1647

Does Statistical Decrease of Mortality Rates by a Factor of about 2.5 Suggest Revolutional Progress in Melanoma Treatment from Year 2009 to 2017?

Ernst-Peter Rührnschopf*

Imaging & Therapy Division, Healthcare Sector, Siemens Medical Systems, Erlangen, Germany

*Correspondance to: Ernst-Peter Rührnschopf 

 PDF  Full Text Short Communication | Open Access

Abstract:

Comparison of mortality rates (for 5 years and 10 years, resp.), derived from the leading AJCC melanoma staging system references from 2009 and 2017, are showing an astounding decrease by a factor of about 2.5 (± 0.1) for different cutaneous melanoma stages, e.g. IIB, IIC, and IIIB, whereas the respective comparison between the former references from 2001 and 2009 amounts only to a factor of about 1.1 (± 0.05). The dramatic improvement in the short time from 2009 to 2017 suggests a revolutional progress in melanoma treatment, perhaps unsurpassed in the history of cancer.

Keywords:

Cite the Article:

Rührnschopf E-P. Does Statistical Decrease of Mortality Rates by a Factor of about 2.5 Suggest Revolutional Progress in Melanoma Treatment from Year 2009 to 2017?. Clin Oncol. 2019; 4: 1647 .

Journal Basic Info

  • Impact Factor: 3.231**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
  • PubMed NLM ID: 101705590

Search Our Journal

Journal Indexed In

Articles in PubMed

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Molecular Pathological Signatures of Gastric Cancer in Koreans Revealed by Label-Free Proteomics
 Abstract  PDF  Full Text
Erlotinib Treatment Beyond Progression in EGFR Mutant Patients Who Have Responded to EGFR TKIs in Stage IIIB/IV NSCLC: An Open Label Randomized Trial
 Abstract  PDF  Full Text
View More...